We are pleased to announce that Emergence is a Bronze-level Partner at this year’s NeuroConX Innovation Exchange conference, which brings together researchers, business leaders, clinical investigators and investment professionals to discuss the latest therapeutic approaches in the treatment of neurodegenerative diseases.
The event will take place at the Prince Edward Island Convention Centre in Charlottetown, Prince Edward Island. Check out the full program here!
The title of the upcoming NeuroConX 2018 conference is: “Mind Your Gut: The Role of the Gut Microbiome in Brain Health and Disease”.
Leading global experts will discuss the latest scientific findings around microbiome effects in various brain disorders, including Parkinson’s disease, Alzheimer’s disease, ALS, autism, schizophrenia, and depression. Industry leaders will discuss ways in which innovators are harnessing the human microbiome and advancing novel therapeutics and diagnostics.
The human microbiota consists of the 10-100 trillion symbiotic microbial cells harbored by each person, primarily bacteria in the gut. Emerging evidence has demonstrated that intestinal homeostasis and the microbiome play essential roles in neurodegenerative diseases, such as Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease, and dementia, as well as neuropsychiatric conditions, such as depression and schizophrenia, and neurodevelopmental conditions, such as autism. The gut-brain axis involves a bidirectional signaling system that gives the gut influence over the brain through multiple processes, affecting immune responses, antioxidant processes, metabolic activity, and neuroplasticity.